CLINICAL TRIALS PROFILE FOR RITUXIMAB; HYALURONIDASE (HUMAN RECOMBINANT)
✉ Email this page to a colleague
All Clinical Trials for rituximab; hyaluronidase (human recombinant)
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03467867 ↗ | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | Recruiting | Hackensack Meridian Health | Phase 2 | 2018-04-26 | This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL). |
| NCT03467867 ↗ | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | Recruiting | Georgetown University | Phase 2 | 2018-04-26 | This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL). |
| NCT03719131 ↗ | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | Recruiting | Genentech, Inc. | Phase 2 | 2019-06-05 | This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy. |
| NCT03719131 ↗ | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | Recruiting | Emory University | Phase 2 | 2019-06-05 | This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy. |
| NCT03864419 ↗ | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | Recruiting | Fred Hutchinson Cancer Research Center | Phase 1 | 2019-10-24 | This phase I trial studies how well rituximab hyaluronidase and combination chemotherapy work in treating patients in Uganda with Burkitt lymphoma, diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated multicentric Castleman disease. Rituximab hyaluronidase is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is faster than giving rituximab alone by infusion into the blood. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, methotrexate, etoposide, doxorubicin, and prednisone work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. While rituximab has a clear survival benefit in patients within developed countries, differences in supportive care and infectious co-morbidities require special attention. Giving rituximab hyaluronidase alone or in combination with chemotherapy may work better in treating patients with Burkitt lymphoma, diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated multicentric Castleman disease compared to chemotherapy alone in Uganda. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for rituximab; hyaluronidase (human recombinant)
Condition Name
| Condition Name for rituximab; hyaluronidase (human recombinant) | |
| Intervention | Trials |
| Diffuse Large B-Cell Lymphoma | 2 |
| Refractory Marginal Zone Lymphoma | 2 |
| Recurrent Marginal Zone Lymphoma | 2 |
| Refractory B-Cell Non-Hodgkin Lymphoma | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for rituximab; hyaluronidase (human recombinant)
Trials by Country
Clinical Trial Progress for rituximab; hyaluronidase (human recombinant)
Clinical Trial Phase
Clinical Trial Sponsors for rituximab; hyaluronidase (human recombinant)
Sponsor Name
| Sponsor Name for rituximab; hyaluronidase (human recombinant) | |
| Sponsor | Trials |
| National Cancer Institute (NCI) | 4 |
| Academic and Community Cancer Research United | 2 |
| Fred Hutchinson Cancer Research Center | 1 |
| [disabled in preview] | 2 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
